Added value of inflammatory plasma biomarkers to pathologic biomarkers in predicting preclinical Alzheimer's disease
Journal of Alzheimer’s Disease · 2024
DOI: 10.1177/13872877241283692 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Haley Leclerc und 3 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, RI, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Amyloid beta-Peptides, tau Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIGMS NIH HHS, National Institute of General Medical Sciences.
Themen: Demenz
Abstract (Originalsprache)
Background
Plasma biomarkers have recently emerged for the diagnosis, assessment, and disease monitoring of Alzheimer's disease (AD), but have yet to be fully validated in preclinical AD. In addition to AD pathologic plasma biomarkers (amyloid-β (Aβ) and phosphorylated tau (p-tau) species), a proteomic panel can discriminate between symptomatic AD and cognitively unimpaired older adults in a dementia clinic population.
Objective
Examine the added value of a plasma proteomic panel, validated in symptomatic AD, over standard AD pathologic plasma biomarkers and demographic and genetic (apolipoprotein ( APOE) ɛ4 status) risk factors in detecting preclinical AD.
Methods
125 cognitively unimpaired older adults (mean age = 66 years) who completed Aβ PET and plasma draw were analyzed using multiple regression with Aβ PET status (positive versus negative) as the outcome to determine the best fit for predicting preclinical AD. Model 1 included age, education, and gender. Model 2 and 3 added predictors APOE ɛ4 status (carrier versus non-carrier) and AD pathologic blood biomarkers (Aβ 42/40 ratio, p-tau181), respectively. Random forest modeling established the 5 proteomic markers from the proteomic panel that best predicted Aβ PET status, and these markers were added in Model 4.
Results
The best model for predicting Aβ PET status included age, years of education, APOE ɛ4 status, Aβ 42/40 ratio, and p-tau181. Adding the top 5 proteomic markers did not significantly improve the model.
Conclusions
Proteomic markers in plasma did not add predictive value to standard AD pathologic plasma biomarkers in predicting preclinical AD in this sample.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, RI, USA.
- Butler Hospital Memory & Aging Program, Providence, RI, USA.
- Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, USA.
- Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, USA.
ORCID-Profile: Jessica Alber
Förderung
- NIA NIH HHS
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Leclerc, H., Lee, A. K., Kunicki, Z. J., & Alber, J. (2024). Added value of inflammatory plasma biomarkers to pathologic biomarkers in predicting preclinical Alzheimer's disease. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877241283692
Vancouver
Leclerc H, Lee AK, Kunicki ZJ, Alber J. Added value of inflammatory plasma biomarkers to pathologic biomarkers in predicting preclinical Alzheimer's disease. Journal of Alzheimer’s Disease. 2024. doi:10.1177/13872877241283692
BibTeX
@article{Leclerc2024,
author = {Leclerc, Haley and Lee, Athene Kw and Kunicki, Zachary J and Alber, Jessica},
title = {Added value of inflammatory plasma biomarkers to pathologic biomarkers in predicting preclinical Alzheimer's disease},
journal = {Journal of Alzheimer’s Disease},
year = {2024},
doi = {10.1177/13872877241283692}
}
EUVIMED